A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.

@article{Jallal2007ASK,
  title={A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.},
  author={Houda Jallal and Maria-Luisa Valentino and Gaoping Chen and Frank Boschelli and Suhad A. Ali and Shafaat A. Rabbani},
  journal={Cancer research},
  year={2007},
  volume={67 4},
  pages={1580-8}
}
The central role of Src in the development of several malignancies, including breast cancer, and the accumulating evidence of its interaction with receptor tyrosine kinases, integrins, and steroid receptors have identified it as an attractive therapeutic target. In the current study, we have evaluated the effect of a Src/Abl kinase inhibitor, SKI-606, on breast cancer growth, migration, invasion, and metastasis. Treatment of human breast cancer cells MDA-MB-231 with SKI-606 caused a marked… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

Dasatinib : a novel therapy for breast cancer?

Expert opinion on investigational drugs • 2013
View 3 Excerpts
Highly Influenced

Src as a Therapeutic Target in Biliary Tract Cancer.

Molecular cancer therapeutics • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Angiogenesis: the VE-cadherin switch.

Trends in cardiovascular medicine • 2006
View 1 Excerpt

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Proceedings of the National Academy of Sciences of the United States of America • 2005

A renaissance for SRC

Nature Reviews Cancer • 2004
View 1 Excerpt

Similar Papers

Loading similar papers…